Quick Facts

• Primary Function: Is utilized for the temporary relief of symptoms associated with allergic conditions.
• Key Indications: May contribute to the management of symptoms from allergic rhinitis and urticaria (hives).
• Supports Relief of: Manifestations of atopic and hypersensitivity reactions.

---

What Supranorm-Tsiteli A Treats: Main Uses and Benefits

Supranorm-Tsiteli A is used in therapeutic contexts for the temporary relief of symptoms linked to certain allergic conditions. The medication may contribute to the management of discomfort associated with seasonal and perennial allergic rhinitis, commonly known as hay fever. This includes the temporary relief of sneezing, runny nose, and itching of the eyes, nose, or throat that occurs in these conditions.

Additionally, the drug is indicated for the management of urticaria, which presents as hives or allergic skin reactions. Supranorm-Tsiteli A may also offer relief from symptoms of allergic conjunctivitis and other manifestations of atopic or hypersensitivity reactions as determined by a healthcare professional.

Eligibility Map: Who Can and Cannot Use Supranorm-Tsiteli A — Official Regulatory Information

This map summarizes the official population eligibility and non-eligibility information for Supranorm-Tsiteli A (Chloropyramine Hydrochloride), based strictly on government regulatory documents for the active substance class.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults and children 12 years of age and older.
	Children 6 to under 12 years of age.
Populations for whom use is not recommended (if applicable)	Children under 6 years of age. Safety and effectiveness not established.
	Older Adults (Geriatric) due to increased risk of effects.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Chloropyramine Hydrochloride.
	Patients treated with Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.
	Patients with narrow-angle glaucoma or urinary retention due to prostatic hypertrophy.
	Premature and newborn infants.
Pregnancy and lactation eligibility status (if explicitly documented)	Not to be used during pregnancy or lactation unless deemed essential by a physician.
Eligibility-related restrictions	Conditional use, requiring caution, for patients with hepatic impairment, renal impairment, severe hypertension, severe cardiovascular disease, or epilepsy.

---

Eligibility Classifications (High-Level)

Category	Official Regulatory Wording (as defined in official documents)
Eligibility severity classification (as defined in official documents)	Contraindicated; Not Recommended; Use with Caution; Use not established.
Eligibility-context constraints (as defined in official documents)	Hypersensitivity; Concomitant MAOI Therapy; Underlying Anticholinergic-Exacerbating Conditions; Pediatric Age Threshold; Organ Function (Hepatic/Renal Impairment).

Connection to the overall eligibility profile: Official regulatory documents strictly define the permissible use of Supranorm-Tsiteli A by establishing absolute prohibitions based on patient status, such as MAOI use, and specific conditions like narrow-angle glaucoma. Eligibility for all other populations, including children and those with organ impairment, is determined by mandatory conditional use requirements or specific regulatory recommendations documented in official labeling.

Supranorm-Tsiteli A, containing Chloropyramine Hydrochloride, has officially documented interaction patterns primarily involving additive effects and metabolic changes, as defined in regulatory documentation.

Documented Pharmacodynamic and Substance Interactions

Co-administration with Central Nervous System (CNS) Depressants, including Alcohol (Ethanol), results in a pharmacodynamic interaction that enhances the sedative effects. Similarly, combining the medicine with Anticholinergic Drugs causes an additive antimuscarinic action, which may increase the risk of related symptoms. The drug is also noted to potentially mask the warning signs of ototoxicity when used concurrently with certain Ototoxic Drugs, such as Aminoglycoside antibiotics.

Official Restrictions and Exposure-Altering Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formally documented contraindicated combination. This prohibition is sometimes accompanied by a mandatory timing restriction, requiring that the drugs be separated by a specified period (e.g., 14 days) upon discontinuation of MAOI therapy. A pharmacokinetic interaction is also documented, where the drug may inhibit the hepatic metabolism of co-administered substances like Phenytoin. This results in an increased plasma concentration and elevated exposure of Phenytoin, which is a critical consideration noted in regulatory prescribing information.

Interference with Peripheral Histamine Signaling and Vascular Response

Supranorm-Tsiteli A's primary mechanism involves competitive antagonism at the Histamine H1 Receptor expressed on vascular endothelial cells and sensory nerve endings. By stabilizing the receptor in an inactive state, the compound blocks the action of endogenous histamine, which in turn inhibits vasodilation and reduces capillary permeability. This molecular action directly reduces microvascular leakage and inhibits histamine-driven sensory nerve excitation.

---

Action on Central Neuronal Arousal Pathways and Secondary Receptors

The molecule readily crosses the blood-brain barrier to affect the central nervous system (CNS), engaging in two key secondary mechanisms. It blocks central H1 receptors, which are involved in the brain's wake-promoting pathways, and also acts as an antagonist at Muscarinic Acetylcholine Receptors (mAChR). This dual CNS activity results in a reduction of central histamine-dependent neuronal activity and influences autonomic signaling, establishing a characteristic profile of physiological consequences.

How to Use Supranorm-Tsiteli A: Administration Guidelines

This section describes the guidelines for administering Supranorm-Tsiteli A (Chloropyramine Hydrochloride). These parameters define the routes, dosages, and preparation steps for the medicine.

---

Approved Routes and Dosage Forms

Route of Administration	Available Forms (Examples)	Administration Context
Oral	Tablet (Immediate-Release 4 mg); Extended-Release Tablet	Symptomatic use
Parenteral	Injectable Solution (e.g., 10 mg/mL)	Acute systemic situations
Topical	Cream or Ointment (1%)	Localized skin application

Standard Dosing Regimens (Adults)

Guidelines establish limits on the quantity and frequency of administration:

• Oral (Immediate-Release): The typical dose is 4 mg per administration, to be taken every 4 to 6 hours as needed. The total dose must not exceed 24 mg in a 24-hour period.
• Parenteral (Injection): Dosing for acute systemic use is typically 10 mg to 20 mg per injection, which may be repeated according to specific product parameters.

Special Instructions and Duration of Use

Administration Conditions:

• Extended-Release Tablets: Must be swallowed whole; they should not be crushed or chewed, as this alters the drug's sustained-release properties.
• Intravenous (IV) Use: The injection must be administered slowly (e.g., over a one-minute period) when given intravenously.
• Oral Intake: The immediate-release tablet can generally be administered with or without food.

Population-Specific Rules: Dosing for children (e.g., ages 6 to 12 years) is generally half the adult dose, with a daily limit of 12 mg for the immediate-release tablet.

Duration Constraint: The medication is intended for temporary relief only. The duration of continuous oral use is limited, with the parameter not to take the medicine for more than two weeks without professional guidance.

The information below summarizes the clinical research structure and reported observations for Chloropyramine Hydrochloride (the active ingredient in Supranorm-Tsiteli A) as reported in official and peer-reviewed scientific sources. The research provides context and highlights what is known—and what is still uncertain—about this compound.

---

Evidence for Use in Allergic Rhinitis (Hay Fever)

Research has focused on conditions characterized by fluctuating symptoms, such as allergic rhinitis. Studies include Randomized Controlled Trials (RCTs) examining outcomes related to physical discomfort like sneezing and itching. Trials typically assess short-term symptom patterns over periods up to six weeks. Follow-up durations were limited, and long-term outcomes are not fully established. Comparisons with more recently developed compounds are also limited for this specific agent.

---

Evidence for Use in Urticaria (Hives)

This medicine was also evaluated in research for urticaria. Studies include RCTs that explored outcomes describing episodic changes by measuring itch intensity and the number and duration of weals (hives). Research highlights changes measured during the study period, with the overall evidence base for addressing outcomes related to physical discomfort generally assigned a Moderate level. Research often focuses on the H1-antihistamine class rather than providing extensive dedicated data for this specific compound.

---

Research Gaps and Special Populations

Most of the foundational research was evaluated in general populations of adults. Specific data for certain groups, such as children, older adults, or individuals with complex coexisting non-allergic conditions, may be limited. Overall, comparative evidence is lacking for this compound against many contemporary standard treatments, and sample sizes were modest in some specialized trials, meaning the results apply only to the populations studied.

Common questions about Supranorm-Tsiteli A (FAQ)

Q: What is Supranorm-Tsiteli A used for?

Supranorm-Tsiteli A is an antihypertensive medication. It is primarily used to treat high blood pressure (hypertension) to help prevent stroke, heart attack, and kidney problems. It may also be used to manage certain types of congestive heart failure and to improve survival after a heart attack.

Q: How should I take Supranorm-Tsiteli A?

Take Supranorm-Tsiteli A exactly as your healthcare provider prescribes. It is usually taken once a day, with or without food. Try to take your dose at the same time each day to maintain a consistent level of medication in your body. Do not stop taking it suddenly without talking to your doctor.

Q: What are common side effects of Supranorm-Tsiteli A?

Common side effects can include dizziness or lightheadedness (especially when standing up), fatigue, headache, and a dry, persistent cough. If these effects are severe or do not go away, contact your healthcare provider.

Q: Can I drink alcohol while taking Supranorm-Tsiteli A?

It is generally recommended to limit or avoid alcohol while taking Supranorm-Tsiteli A. Alcohol can increase the blood pressure-lowering effects of the medication, leading to excessive dizziness or fainting. Discuss your alcohol consumption with your doctor.

Q: What if I miss a dose of Supranorm-Tsiteli A?

If you miss a dose, take it as soon as you remember. If it is close to the time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take a double dose to make up for a missed one.

How to Store and Dispose of Supranorm-Tsiteli A

Storage of Supranorm-Tsiteli A must strictly adhere to the conditions mandated by regulatory labeling to ensure product stability. The medication must be kept at a controlled room temperature, typically 20 C to 25 C, and stored in its original container with the lid tightly closed.

Required Protection

Condition	Requirement
Temperature	Store away from excessive heat.
Environment	Protect from moisture and light.
Prohibited	The liquid/injectable form must not be frozen.

Handling and Disposal

All official labeling mandates that Supranorm-Tsiteli A must be stored out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired medication must be handled according to local pharmaceutical waste regulations and should not be discarded in household wastewater (sinks or toilets).